热性惊厥病史对四价麻腮风-水痘疫苗热性惊厥风险差的影响:匹配队列研究的事后探索性分析
该事后分析基于匹配队列研究,比较低风险人群接种首剂四价麻腮风-水痘疫苗(MMRV)后5-12天热性惊厥(FC)风险与分别接种麻腮风疫苗(MMR)和水痘疫苗(V)的差异。排除有FC个人史(情景1)及有FC个人史和/或家族史(情景2)的儿童后,情景2接种MMRV的FC发生率(36.3-49.5/10万)与全队列接种MMR+V的FC发生率(43.6/10万)相近;与全队列相比,情景1风险差增加0.2例/10万,情景2风险差降低5.3-8.6例/10万。结论认为仅对有FC个人史或家族史的儿童接种MMRV可降低首剂接种后FC总体风险。
要点
- 情景2接种MMRV的FC发生率(36.3-49.5/10万)与全队列接种MMR+V(43.6/10万)相近。
- 与全队列相比,情景1风险差增加0.2例/10万,情景2风险差降低5.3-8.6例/10万。
- 仅对无FC个人史或家族史的儿童接种MMRV可降低首剂接种后FC总体风险。
核心结论
- 仅对有FC个人史或家族史的儿童接种MMRV可降低首剂接种后FC总体风险。
研究设计与样本
- 匹配队列研究的事后探索性分析,比较低风险人群接种首剂MMRV后5-12天FC风险与分别接种MMR和V疫苗的差异。
主要发现
- 情景2接种MMRV的FC发生率为36.3-49.5/10万,全队列接种MMR+V的FC发生率为43.6/10万,两者相近。
- 与全队列相比,情景1的FC风险差增加0.2例/10万,情景2的FC风险差降低5.3-8.6例/10万。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This post-hoc analysis of data from a matched cohort study investigated the risk of febrile convulsions (FC) 5-12 days post-first dose of measles-mumps-rubella-varicella vaccine (MMRV) in a low-risk population, compared to measles-mumps-rubella (MMR) and varicella (V) vaccines administered separately. The low-risk population excluded children with personal history of FC (Scenario 1) and children with personal or/and family history (≥1 parent/sibling) of FC (Scenario 2). Incidence of FC post-MMRV in Scenario 2 (excluding at risk children) (36.3-49.5/100,000) and post-MMR+V in the whole cohort including children with personal/family history of FC (43.6/100,000) were similar. The risk difference of FC increased by 0.2 case/100,000 in Scenario 1 and decreased by 5.3-8.6 cases/100,000 of vaccinated children in Scenario 2, compared to the whole cohort. The overall risk of FC post-first dose MMRV vaccination could be lowered by administering MMRV only to children with no personal or family history of FC.
引用
- Gvozdenovic E, Vetter V, Willame C, et al. Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: Post-hoc exploratory analysis of results from a matched-cohort study. Vaccine. 2018. PMID: 30131195. doi:10.1016/j.vaccine.2018.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。